ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
70,350.33
0.31%
S&P 500
5,320.92
-0.01%
Dow Jones
39,849.93
-0.06%
US Dollar vs Yen
156.489
0.15%
Brent Oil
82.195
-0.30%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Cogent Biosciences Inc (COGT)

  7. Cogent Biosciences Inc (COGT) ニュース

COGT

Cogent Biosciences (COGT)

Cogent Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:COGT
日付受信時刻ニュースソース見出しコード企業名
2024/05/0721 : 26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
2024/05/0721 : 19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2024/05/0721 : 00GlobeNewswire Inc.Cogent Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
2024/04/0922 : 00GlobeNewswire Inc.Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorNASDAQ:COGTCogent Biosciences Inc
2024/02/2706 : 34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:COGTCogent Biosciences Inc
2024/02/2623 : 13Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:COGTCogent Biosciences Inc
2024/02/2622 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2024/02/2622 : 00GlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
2024/02/2304 : 30GlobeNewswire Inc.Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisNASDAQ:COGTCogent Biosciences Inc
2024/02/1708 : 55Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:COGTCogent Biosciences Inc
2024/02/1708 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/02/1506 : 05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COGTCogent Biosciences Inc
2024/02/1502 : 51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:COGTCogent Biosciences Inc
2024/02/1422 : 35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2024/02/1421 : 00GlobeNewswire Inc.Cogent Biosciences Announces Oversubscribed $225 Million Private PlacementNASDAQ:COGTCogent Biosciences Inc
2024/02/1006 : 22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COGTCogent Biosciences Inc
2024/02/0523 : 00GlobeNewswire Inc.Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual MeetingNASDAQ:COGTCogent Biosciences Inc
2024/01/2606 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/01/2606 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/01/2606 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/01/2606 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/01/0922 : 00GlobeNewswire Inc.Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted TherapeuticsNASDAQ:COGTCogent Biosciences Inc
2024/01/0506 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/01/0222 : 00GlobeNewswire Inc.Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:COGTCogent Biosciences Inc
2023/12/1122 : 04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2023/12/1121 : 55GlobeNewswire Inc.Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)NASDAQ:COGTCogent Biosciences Inc
2023/12/1003 : 30GlobeNewswire Inc.Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)NASDAQ:COGTCogent Biosciences Inc
2023/12/0723 : 00GlobeNewswire Inc.Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer SymposiumNASDAQ:COGTCogent Biosciences Inc
2023/12/0422 : 00GlobeNewswire Inc.Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual MeetingNASDAQ:COGTCogent Biosciences Inc
2023/11/2922 : 00GlobeNewswire Inc.Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer SymposiumNASDAQ:COGTCogent Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:COGT

最近閲覧した銘柄

USOTC
BASFY
BASF (QX)
NYSE
VZ
Verizon Communications
CCOM
US30
US 30
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
FX
USDJPY
US Dollar vs Yen
USI
USTECH100
US Tech 100
CCOM
SILVER
SILVER
NASDAQ
TSLA
Tesla
NASDAQ
NVDA
NVIDIA
FX
USDEUR
US Dollar vs Euro
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有